You just read:

Overall survival data from LUX-Lung 7 head-to-head trial of Gilotrif® (afatinib) versus Iressa® (gefitinib) presented at ESMO

News provided by

Boehringer Ingelheim

Oct 09, 2016, 08:05 ET